Poolbeg Pharma: Further data shows POLB001 potential in cancer CRS

Key highlights from today's POLB RNS include:

- Efficacy is demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model

- New data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS.

Read the full RNS here.